Nanogam (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Nanogam, is an immunoglobulin preparation presented as a solution for injection for intravenous use. It provides passive immunity and modulates immune system activity in patients with primary or secondary immunodeficiency, immune thrombocytopenic purpura, and Kawasaki disease.

GNH USA supplies Nanogam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, conforming to EU quality standards.

Nanogam is used to replace deficient IgG antibodies in disorders affecting humoral immunity.

- Primary immunodeficiency diseases: restores normal IgG levels to reduce infection frequency. - Secondary immunodeficiency: provides passive immunity when endogenous production is compromised. - Immune thrombocytopenic purpura (ITP): modulates immune response to increase platelet counts. - Kawasaki disease: helps control inflammation and reduces risk of coronary artery complications.

Nanogam may be associated with infusion‑related reactions and immunologic events.

Common Side Effects: - Headache: mild to moderate pain in the head. - Fever: transient elevation of body temperature. - Chills: shaking sensation during or after infusion. - Injection site reactions: redness, swelling or discomfort at the infusion site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction that can be life‑threatening. - Aseptic meningitis: inflammation of the meninges without infection. - Thromboembolic events: formation of blood clots in veins or arteries. - Renal dysfunction: impaired kidney function that may require monitoring.

Before using Nanogam, clinicians should consider several safety measures.

- Patient assessment: evaluate immunoglobulin levels and infection history before initiating therapy. - Infusion rate: start at a slow rate and increase gradually to reduce reactions. - Concomitant immunosuppressants: monitor for additive immunosuppression. - Renal function: assess baseline kidney function and adjust infusion if impairment exists. - Pregnancy and lactation: use only if potential benefit justifies potential risk; data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nanogam can interact with other medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Live vaccines: may reduce vaccine efficacy and increase risk of infection. - High‑dose steroids: can amplify immunosuppressive effects. - Anticoagulants: increased risk of bleeding due to potential platelet changes.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor blood pressure for hypotensive episodes. - Diuretics: watch for fluid shifts during infusion. - Rituximab: assess for additive immunosuppression.